Esbriet is an oral medicine approved for the treatment of IPF and is available in approximately 40 countries worldwide. Esbriet has Orphan Drug Designation and was approved for use in Europe in 2011 in adults with mild-to-moderate IPF and in the US in people with IPF in October 2014.
In 2017, the U.S. Food and Drug Administration (FDA) and the European Commission approved the Esbriet 801 mg and 267 mg tablets as new options for administering the medicine for the treatment of IPF. The new 801 mg tablets offer people with IPF a maintenance option for taking Esbriet with fewer pills per day.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.